Trial Profile
Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD) - A Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2020
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors SCRI Development Innovations
- 13 Feb 2020 Status changed from active, no longer recruiting to completed.
- 28 May 2019 Planned End Date changed from 1 Jan 2019 to 31 Jan 2020.
- 28 May 2019 Planned primary completion date changed from 1 Jan 2019 to 31 Jan 2020.